Lung Cancer (Respiratory Cancers) VA Rating

Overview

Lung cancer is presumptive for Agent Orange-exposed veterans (Vietnam-era) and PACT Act-eligible veterans.

After active treatment, residuals frequently include reduced PFTs, scarring, and post-thoracotomy pain.

In Depth

Respiratory cancers — lung, bronchus, larynx, and trachea — are Agent Orange presumptive under 38 CFR § 3.309(e), and the PACT Act added a broad set of respiratory cancers for veterans with qualifying burn-pit and toxic-exposure service, along with several non-malignant respiratory conditions.

Evaluation is under 38 CFR § 4.97, Diagnostic Code 6819 for malignant neoplasms of the respiratory system. Malignancies rated at 100 percent under 38 CFR Part 4 carry a note directing that the total evaluation continues during active disease and for six months following the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. VA must then schedule a mandatory examination, and any reduction from the 100 percent evaluation is made under the procedures in 38 CFR § 3.105(e) — advance written notice, at least 60 days to submit evidence, and 30 days to request a predetermination hearing. If the mandatory exam did not happen, or the notice period was not honored, that is a procedural issue separate from the medical question of how bad the residuals are.

After the convalescent period, the evaluation is built from residuals, each rated under the diagnostic code for the affected body system and combined under 38 CFR § 4.25. Common residuals that go unrated because no one claimed them include chemotherapy-induced peripheral neuropathy, fatigue, cognitive complaints, hypothyroidism after radiation to the neck, voiding dysfunction, erectile dysfunction with special monthly compensation for loss of use of a creative organ under 38 CFR § 3.350(a), surgical scars, and mental health conditions secondary to the diagnosis and treatment. After lung cancer treatment the residuals are usually respiratory: reduced pulmonary function after lobectomy or pneumonectomy, radiation pneumonitis or fibrosis, chronic cough and dyspnea, thoracotomy scars, and in many cases a coexisting obstructive disease that was there before.

Post-treatment respiratory evaluations turn on pulmonary function testing — FEV-1, FEV-1/FVC, and DLCO — measured post-bronchodilator where applicable. A residuals evaluation performed without current PFTs is a thin record, and that is a fixable evidentiary problem rather than an argument about severity.

How to Establish Service Connection

• Presumptive: Agent Orange (Vietnam, Korean DMZ, Thailand) and PACT Act (post-9/11 burn pit / airborne hazard).
• Direct: documented carcinogen exposure in service.

Rating Criteria

Paraphrased from 38 CFR § 4.97, Diagnostic Code 6819

See what each percentage pays in 2026 and how it combines with your current rating →

Evidence Checklist

• Pathology and staging.
• Treatment records (surgery, chemo, radiation).
• Post-treatment PFTs.
• Exposure documentation.

Evidence VA Commonly Cites in These Claims

Descriptive summary of evidence types frequently referenced in rating decisions for this condition. Not a checklist of actions to take — every claim is decided on its own facts.

• ★Get the pathology report and the oncology treatment summary into the file — the dates therapy started and stopped are what set the six-month convalescent window.
• ★List every residual separately when the issue is evaluated after treatment; residuals that are never identified are generally never rated.
• ★Ask the treating oncologist to document ongoing surveillance, maintenance therapy, or hormone therapy where it applies — continuing therapy can be relevant to whether the active-disease evaluation should have continued.
• ★For presumptive exposure, put the service documentation in the file: DD-214, unit assignments, deployment orders, or the location and date range establishing covered service.
• ★Where a reduction from 100 percent is proposed, respond within the 60-day evidence window and request the predetermination hearing within 30 days if you want one — those windows are separate.
• ★Get current pulmonary function testing with DLCO into the record before the post-treatment evaluation is decided.
• ★Document surgical extent — wedge resection, lobectomy, or pneumonectomy — since the functional loss differs substantially.
• ★Identify any coexisting service-connected respiratory condition so the evaluations are considered together rather than in isolation.

Illustrative Scenarios

These are hypothetical educational examples — not actual case results, predictions, or guarantees of outcomes.

Common pitfalls VA sees

• Assuming the 100 percent evaluation continues indefinitely. It does not; the schedule contemplates reevaluation six months after therapy ends.
• Letting the mandatory post-treatment examination pass without documenting residuals, then disagreeing only after the reduction takes effect.
• Claiming only the cancer and never claiming the neuropathy, scars, fatigue, endocrine, or mental health residuals it produced.
• Missing the 60-day evidence window in a proposed-reduction letter because it looks like a form letter rather than a deadline.

Common Secondary Conditions

Conditions frequently service-connected as secondary to Lung Cancer (Respiratory Cancers):

What the C&P Exam Documents

General information about how this condition is typically evaluated. This is not coaching on what to say and is not a substitute for medical or legal advice.

• →Ask whether pulmonary function testing will be performed; the respiratory criteria are numeric.
• →Describe exertional limits in distances and stairs, not adjectives.
• →Report oxygen use, nebulizer use, and hospitalizations over the past year.

Frequently Asked Questions